Scholar Rock Holding (SRRK) Amortization of Deferred Charges (2019 - 2026)
Scholar Rock Holding's quarterly Amortization of Deferred Charges came in at $34000.0 in Q1 2026, down 92.41% year-on-year from $448000.0 in Q1 2025, and down 65.31% quarter-over-quarter from $98000.0 in Q4 2025.
Scholar Rock Holding has reported Amortization of Deferred Charges for 7 years, with the latest figure at $34000.0 in Q1 2026.
- For the quarter ending Q1 2026, Amortization of Deferred Charges fell 92.41% year-over-year to $34000.0; the trailing twelve-month figure through Mar 2026 stood at $9000.0 (down 98.56% YoY), and the FY2025 full-year result was $423000.0, up 67.19% from the prior year.
- Amortization of Deferred Charges for Q1 2026 stood at $34000.0, down from $98000.0 in the prior quarter.
- The five-year high for Amortization of Deferred Charges was $448000.0 in Q1 2025, with the low at -$137000.0 in Q3 2025.
- Average Amortization of Deferred Charges over 5 years is $100235.3, with a median of $72000.0 recorded in 2023.
- Peak annual rise in Amortization of Deferred Charges reached 481.82% in 2025, while the deepest fall reached 292.96% in 2025.
- Tracing SRRK's Amortization of Deferred Charges over 5 years: stood at $147000.0 in 2022, then slumped by 59.86% to $59000.0 in 2023, then fell by 20.34% to $47000.0 in 2024, then surged by 108.51% to $98000.0 in 2025, then sank by 65.31% to $34000.0 in 2026.
- The last three Amortization of Deferred Charges figures came in at $34000.0 (Q1 2026), $98000.0 (Q4 2025), and -$137000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Scholar Rock Holding | 500.61 Mn | 20.67 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 34,000.00 |
| Mar 31, 2026 | 34,000.00 |
| Dec 31, 2025 | 98,000.00 |
| Dec 31, 2025 | 98,000.00 |
| Sep 30, 2025 | -137,000.00 |
| Sep 30, 2025 | -137,000.00 |
| Jun 30, 2025 | 14,000.00 |
| Jun 30, 2025 | 14,000.00 |
| Mar 31, 2025 | 448,000.00 |
| Mar 31, 2025 | 448,000.00 |
| Dec 31, 2024 | 47,000.00 |
| Dec 31, 2024 | 47,000.00 |
| Sep 30, 2024 | 71,000.00 |
| Sep 30, 2024 | 71,000.00 |
| Jun 30, 2024 | 58,000.00 |
| Jun 30, 2024 | 58,000.00 |
| Mar 31, 2024 | 77,000.00 |
| Mar 31, 2024 | 77,000.00 |
| Dec 31, 2023 | 59,000.00 |
| Dec 31, 2023 | 59,000.00 |
| Sep 30, 2023 | 58,000.00 |
| Sep 30, 2023 | 58,000.00 |
| Jun 30, 2023 | 72,000.00 |
| Jun 30, 2023 | 72,000.00 |
| Mar 31, 2023 | 85,000.00 |
| Mar 31, 2023 | 85,000.00 |
| Dec 31, 2022 | 147,000.00 |
| Dec 31, 2022 | 147,000.00 |
| Sep 30, 2022 | 184,000.00 |
| Sep 30, 2022 | 184,000.00 |
| Jun 30, 2022 | 191,000.00 |
| Jun 30, 2022 | 191,000.00 |
| Mar 31, 2022 | 198,000.00 |
| Mar 31, 2022 | 198,000.00 |
| Dec 31, 2021 | 87,000.00 |
| Dec 31, 2021 | 87,000.00 |
| Sep 30, 2021 | 81,000.00 |
| Sep 30, 2021 | 81,000.00 |
| Jun 30, 2021 | 84,000.00 |
| Jun 30, 2021 | 84,000.00 |
| Mar 31, 2021 | 83,000.00 |
| Mar 31, 2021 | 83,000.00 |
| Sep 30, 2019 | 250,000.00 |
| Sep 30, 2019 | 250,000.00 |
| Jun 30, 2019 | 248,000.00 |
| Jun 30, 2019 | 248,000.00 |
| Mar 31, 2019 | 244,000.00 |
| Mar 31, 2019 | 244,000.00 |